<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564522</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00117706</org_study_id>
    <nct_id>NCT03564522</nct_id>
  </id_info>
  <brief_title>Image-based Multi-scale Modeling Framework of the Cardiopulmonary System: Longitudinal Calibration and Assessment of Therapies in Pediatric Pulmonary Hypertension</brief_title>
  <official_title>Image-based Multi-scale Modeling Framework of the Cardiopulmonary System: Longitudinal Calibration and Assessment of Therapies in Pediatric Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks to develop a multi-scale computational model of Pulmonary Hypertension, this
      clinical model will be calibrated using longitudinal, retrospectively and prospectively
      acquired human clinical data.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>3D volumetric data (mL/m2)</measure>
    <time_frame>1 hour</time_frame>
    <description>Modeling framework will be validated using 3D volumetric data (mL/m2) gathered via cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiopulmonary Flow (mL/beat)</measure>
    <time_frame>1 hour</time_frame>
    <description>Modeling framework will be validated using cardiopulmonary flow (mL/beat) gathered via cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Pressure (mmHg)</measure>
    <time_frame>2 hours</time_frame>
    <description>Modeling framework will be validated using pressures (mmHg) gathered via cardiac catheterization</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Congenital Heart Disease</condition>
  <condition>Pediatric Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Pulmonary Hypertension</arm_group_label>
    <description>Participants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart Transplant</arm_group_label>
    <description>Successful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cardiac catheterization</intervention_name>
    <description>cardiac catheterizations will be clinically indicated and the study will collect this clinical data.</description>
    <arm_group_label>Heart Transplant</arm_group_label>
    <arm_group_label>Pulmonary Hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>If clinically indicated, the study will collect data from MRIs.</description>
    <arm_group_label>Heart Transplant</arm_group_label>
    <arm_group_label>Pulmonary Hypertension</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pulmonary hypertension patients will be defined by a mean artery blood pressure &gt;25 mmHg.
        Transplant patients are tested for pulmonary vascular resistance prior to transplant; if it
        is too high, transplant is contraindicated. So this group comprises patients who have
        normal right ventricular function and pulmonary vascular function to act as a control for
        the right-sided disease that we are testing, and in addition regularly undergo cardiac
        catheterization for clinical purposes.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients has been clinically diagnosed with pulmonary hypertension (&gt;25 mmHg) or
             patient is a biopsy-proven non-rejecting cardiac transplant recipient

          -  Receiving partial or full care from pediatric cardiology team at Mott Children's
             Hospital (may have a primary cardiologist elsewhere).

        Exclusion Criteria:

          -  Girls and women who are pregnant or actively trying to become pregnant

          -  Patients with significant neurocognitive impairment that precludes their ability to
             sign a consent form

          -  Patient has a contraindication to right-heart catheterization (RHC) examination, which
             includes patients with hypoxia and those who have difficulty maintaining supine
             position for the procedure.

          -  Patients with the following genetic syndromes:Trisomy 21 if unable to assent or
             consent, Trisomy 18,Trisomy 13, Other genetic syndromes at the discretion of the
             Primary Investigator

          -  Patients with unrepaired single ventricles (i.e., Pre-Fontan physiology)

          -  Patients who have heart failure and are deemed to be high risk to undergo tests that
             require sedation/anesthesia.

          -  Patients who require IV sedation or general anesthesia for research only MRI

          -  Patients with a pacemaker/internal defibrillator will be excluded from MRI PORTION
             ONLY
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alberto Figueroa, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Afton</last_name>
    <phone>734-232-3945</phone>
    <email>kafton@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mott Children's Hospital University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Afton</last_name>
      <phone>734-232-3945</phone>
      <email>kafton@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Beckman, CNP</last_name>
      <phone>614-355-5763</phone>
      <email>Brian.Beckman@nationwidechildrens.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Alberto Figueroa</investigator_full_name>
    <investigator_title>Edward B Diethrich M.D. Research Professor of Biomedical Engineering and Vascular Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

